纳斯达克交易所向生物制药企业凯瑞玛治疗公司（Carisma Therapeutics Inc.）发出退市警告，因其未能达到持续挂牌交易的最低股价要求。根据监管文件披露，该公司在纳斯达克全球市场交易期间，连续180个交易日收盘价低于1美元门槛，最终未能在2025年7月7日宽限期截止前实现股价达标。
形势严峻之际出现转机。经听证程序审议，纳斯达克批准了凯瑞玛的紧急申请，允许其证券转入纳斯达克资本市场继续交易。这项特殊安排为该公司争取到关键缓冲期，新的合规截止日定为2025年10月7日。在此期间，凯瑞玛必须满足包括最低收盘价在内的所有上市标准，否则将面临强制退市命运。
市场分析人士指出，此次监管宽限实属罕见，反映交易所对创新药企的特殊考量。但三个月倒计时已然开启，凯瑞玛需在有限时间内通过战略合作、业务重组或并股等手段提振股价，这场资本市场的生死时速正在考验管理层的危机应对能力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.